Global Vaccine Adjuvants Market Size, Trends & Growth Opportunity, By Type (Pathogen, Adjuvant Emulsion, Combination, Particulate, and Others), By Route of Administration (Oral, Intranasal, Intramuscular, Intradermal, and Others), By Application, By Region and Forecast from 2022- 2027.
Global Vaccine Adjuvants Market
Global Vaccine Adjuvants Market was valued at USD 485 million in 2021 which expected to reach USD 812.54 million at a CAGR 5.71% from 2022-2027.
An adjuvant is a chemical that is created as a component of a vaccination to improve the vaccine's capacity to induce protection against infection. It helps to stimulate the immune system and allows the antigens and pathogen components in vaccines to trigger long-lasting protective immunity. Adjuvants that are most frequently utilized are aluminum hydroxide and paraffin oil.
Market Drivers
The global market for vaccine adjuvants is anticipated to be driven by the rise in cervical cancer cases as well as other lethal diseases and infectious diseases like Human Papillomavirus (HPV), HIV, and tuberculosis. Additionally, the rise in government funding for R&D, the prevalence of epidermic outbreaks, as well as tactical development exchanges used by businesses, such as acquisitions, agreements, and collaborations, are boosting the expansion of the worldwide vaccine adjuvants market. For instance, the USFDA (Food and Drug Administration) authorized Puma Biotechnology Inc.'s Nerlynx in 2017 for use as an adjuvant treatment for breast cancer.
Additionally, the growing emphasis on the long-term benefits of vaccination against both existing and developing diseases will favorably impact market expansion. Due to the poor immunogenicity of novel vaccine antigens, the necessity of adjuvant research has considerably increased for the development of these products. Additionally, the increased usage of synthetic and recombinant vaccines is anticipated to promote market expansion throughout the course of the projected period.
Market Restraints
Strict regulatory requirements, high development costs for new adjuvants, and high adjuvant toxicity are some of the restraints that are anticipated to slow the growth of the worldwide vaccine adjuvants market. For instance, studies released in the Scientific Reports Journal in 2016 indicated the toxicity of aluminum adjuvants in a variety of clinically authorized human immunizations.
Market Segmentation
On the basis of type, the global vaccine adjuvants market is segmented into a Pathogen, Adjuvant Emulsion, Combination, Particulate, and Others. The particulate type is expected to hold the largest market share in vaccine adjuvants market.  Due to the availability of a wide range of products and greater efficiency against the diseases. Further, market is segmented into route of administration such as Oral, Intranasal, Intramuscular, Intradermal, and Others. The intramuscular segment accounted for the largest market share in due to better immune specificity. On other hand, the market is segmented into application such as Infectious Disease, Cancer, and Others.
Impact of COVID-19
The global market for vaccine adjuvants is anticipated to be driven by the rising COVID-19 epidemic. Most healthcare, pharmaceutical, and biotechnology organizations have focused on treatments, vaccines, and medications against Novel Coronavirus as a result of the epidemic. The majority of the top businesses are concentrating on developing a novel COVID-19 vaccine. Pharmaceutical firms are also putting a high priority on R&D for COVID-19-related diagnostics, therapies, and vaccinations. Over the course of the forecast period, all of these factors are anticipated to support the expansion of the worldwide vaccine adjuvants market.
Regional Analysis
The Global Vaccine Adjuvants Market is segmented into five regions such as North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.
Due to widespread use of cutting-edge products and the presence of significant market players in this region, particularly in the United States, the North America region maintains the leading position in terms of revenue in the global market for vaccine adjuvants. The development of the market for vaccine adjuvants in this region is also attributed to favourable government backing for the expansion of the healthcare infrastructure. Additionally, the APAC region was predicted to have the quickest market growth due to the region's constantly improving healthcare infrastructure, including the accessibility of medications, as well as an increase in investment for research and development to address the region's enormous unmet demand. Over the course of the forecast, this is anticipated to increase market share.
Key Players
Some of the key players are listed in this report such as Novavax, Inc., GlaxoSmithKline plc., Puma Biotechnology, SEPPIC Inc., Aphios, OZ Biosciences, Agenus,Inc., Hayashibara Co., Ltd., Invivogen, MPV Technologies, etc. These companies are adopting strategies like collaborations, mergers & acquisitions, and new product development. For instance, in July 2017, GSK had collaborated with Exscientia for the development of new drugs.
Market Taxonomy
By Type
•        Pathogen
•        Adjuvant Emulsion
•        Combination
•        Particulate
•        Others
By Route of Administration
•        Oral
•        Intranasal
•        Intramuscular
•        Intradermal
•        Others
By Application
•        Infectious Disease
•        Cancer
•        Others
By Region
•        North America
•        Latin America
•        Europe
•        Asia Pacific
•        Middle East & Africa

Global Vaccine Adjuvants Market TOC:
1 Introduction        
1.1 Objective of the Study
1.2 Market definition
1.3 Market Scope
2 Research Methodology
2.1 Data Mining
2.2 Validation
2.3 Primary Interviews
2.4 List of Data Sources
3 Executive Summary
4 Global Vaccine Adjuvants Market Outlook
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 Global Vaccine Adjuvants Market, By Type
5.1 Y-o-Y Growth Comparison, By Type 
5.2 Global Vaccine Adjuvants Market Share Analysis, By Type 
5.3 Global Vaccine Adjuvants Market Size and Forecast, By Type
5.3.1 Pathogen
5.3.2. Adjuvant Emulsion
5.3.3. Combination
5.3.4. Particulate
5.3.5. Others
6 Global Vaccine Adjuvants Market, By Route of Administration
6.1 Y-o-Y Growth Comparison, By Route of Administration
6.2 Global Vaccine Adjuvants Market Share Analysis, By Route of Administration
6.3 Global Vaccine Adjuvants Market Size and Forecast, By Route of Administration
6.3.1 Oral
6.3.2 Intranasal
6.3.3 Intramuscular
6.3.4 Intradermal
6.3.5. Others
7 Global Vaccine Adjuvants Market, By Application
7.1 Y-o-Y Growth Comparison, By Application
7.2 Global Vaccine Adjuvants Market Share Analysis, By Application
7.3 Global Vaccine Adjuvants Market Size and Forecast, By Application
7.3. 1 Infectious Disease
7.3.2. Cancer
7.3.3. Others
8Global Vaccine Adjuvants Market, By Region
8.1 Global Vaccine Adjuvants Market Share Analysis, By Region
8.2 Global Vaccine Adjuvants Market Share Analysis, By Region
8.3 Global Vaccine Adjuvants Market Size and Forecast, By Region
9 North America Vaccine Adjuvants Market Analysis and Forecast (2022-2027)
9.1 Introduction
9.2 North America Vaccine Adjuvants Market Share Analysis, By Type
9.3 North America Vaccine Adjuvants Market Size and Forecast, By Route of Administration
9.4 North America Vaccine Adjuvants Market Size and Forecast, By Application
9.5 North America Vaccine Adjuvants Market Size and Forecast, By Country
9.5.1 U.S.
9.5.2 Canada
9.5.3 Mexico
10EuropeVaccine Adjuvants Market Analysis and Forecast (2022-2027)
10.1 Introduction
10.2 Europe Vaccine Adjuvants Market Share Analysis, By Type 
10.3 Europe Vaccine Adjuvants Market Size and Forecast, By Route of Administration 
10.4 Europe Vaccine Adjuvants Market Size and Forecast, By Application
10.5 Europe Vaccine Adjuvants Market Size and Forecast, By Country
10.5.1 Germany
10.5.2 France
10.5.3 UK
10.54. Rest of Europe
11Asia Pacific Vaccine Adjuvants Market Analysis and Forecast (2022-2027)
11.1 Introduction
11.2 Asia Pacific Vaccine Adjuvants Market Share Analysis, By Type 
11.3 Asia Pacific Vaccine Adjuvants Market Size and Forecast, By Route of Administration 
11.4 Asia Pacific Vaccine Adjuvants Market Size and Forecast, By Application
11.5 Asia Pacific Vaccine Adjuvants Market Size and Forecast, By Country
11.5.1 China        
11.5.2 Japan
11.5.3 India
11.5.4. Rest of Asia Pacific
12Latin America Vaccine Adjuvants Market Analysis and Forecast (2022-2027)
12.1 Introduction
12.2 Latin America Vaccine Adjuvants Market Share Analysis, By Type 
12.3 Latin America Vaccine Adjuvants Market Size and Forecast, By Route of Administration 
12.4 Latin America Vaccine Adjuvants Market Size and Forecast, By Application
12.5 Latin America Vaccine Adjuvants Market Size and Forecast, Country
13Middle East Vaccine Adjuvants Market Analysis and Forecast (2022-2027)
13.1 Introduction
 13.2 Middle East Vaccine Adjuvants Market Share Analysis, By Type 
13.3 Middle East Vaccine Adjuvants Market Size and Forecast, By Route of Administration 
13.4 Middle East Vaccine Adjuvants Market Size and Forecast, By Application
13.5 Middle East Vaccine Adjuvants Market Size and Forecast, By Country
14Competitive Analysis
14.1 Competition Dashboard
14.2 Market share Analysis of Top Vendors
14.3 Key Development Strategies
15Company Profiles
15.1 Novavax, Inc
15.1.1 Overview
15.1.2 Offerings
15.1.3 Key Financials
15.1.4 Business Segment & Geographic Overview
15.1.5 Key Market Developments
15.1.6 Key Strategies
15.2. GlaxoSmithKline plc
15.2.1 Overview
15.2.2 Offerings
15.2.3 Key Financials
15.2.4 Business Segment & Geographic Overview
15.2.5 Key Market Developments
15.2.6 Key Strategies
15.3. Puma Biotechnology
15.3.1 Overview
15.3.2 Offerings
15.3.3 Key Financials
15.3.4 Business Segment & Geographic Overview
15.3.5 Key Market Developments
15.3.6 Key Strategies
15.4 SEPPIC Inc
15.4.1 Overview
15.4.2 Offerings
15.4.3 Key Financials
15.4.4 Business Segment & Geographic Overview
15.4.5 Key Market Developments
15.4.6 Key Strategies
15.5 Aphios
15.5.1 Overview
15.5.2 Offerings
15.5.3 Key Financials
15.5.4 Business Segment & Geographic Overview
15.5.5 Key Market Developments
15.5.6 Key Strategies
15.6 OZ Biosciences
15.6.1 Overview
15.6.2 Offerings
15.6.3 Key Financials
15.6.4 Business Segment & Geographic Overview
15.6.5 Key Market Developments
15.6.6 Key Strategies
15.7 Agenus,Inc
15.7.1 Overview
15.7.2 Offerings
15.7.3 Key Financials
15.7.4 Business Segment & Geographic Overview
15.7.5 Key Market Developments
15.7.6 Key Strategies        
15.8 Hayashibara Co., Ltd
15.8.1 Overview
15.8.2 Offerings
15.8.3 Key Financials
15.8.4 Business Segment & Geographic Overview
15.8.5 Key Market Developments
15.8.6 Key Strategies
15.9 Invivogen
15.9.1 Overview
15.9.2 Offerings
15.9.3 Key Financials
15.9.4 Business Segment & Geographic Overview
15.9.5 Key Market Developments
15.9.6 Key Strategies
15.10 Invivogen
15.10.1 Overview
15.10.2 Offerings
15.10.3 Key Financials
15.10.4 Business Segment & Geographic Overview
15.10.5 Key Market Developments
15.10.6 Key Strategies